483
Gland Pharma Limited, Units I+II Pashamylaram SiteFDA 483 - Gland Pharma Limited, Units I+II Pashamylaram Site - August 02, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Gland Pharma Limited, Units I+II in Hyderabad, India, from July 25 to August 2, 2024, revealed significant deficiencies in the manufacturing of sterile drug products. The firm was cited for inadequate aseptic processing simulations, poor environmental monitoring practices, and a quality control unit that failed to properly follow procedures, leading to repeated equipment breakdowns and out-of-specification results.
- Inspection Date
- August 2, 2024
- Product Type
- Drugs
Open in Dashboard
ID · ec9c17b8-eaa1-4d9f-aa4a-0631bfca1f54